1-877-439-2744 Motherisk Helpline
1-800-436-8477 Morning Sickness
1-877-327-4636 Alcohol and Substance
1-866-937-7678 Exercise in Pregnancy
1-888-246-5840 HIV and HIV Treatment
416-813-6780 Motherisk Helpline
Pregnancy & Breastfeeding Resources
Current Studies at Motherisk
The Safety of Diclectin in Breastfeeding
Neurodevelopment of Children Exposed in-Utero to Chemotherapy for Maternal Breast Cancer (Dr. I Nulman)
Diclegis Surveillance Program Study
Diclectin Surveillance Program Study
Study seeks women between 4 and 12 weeks in their pregnancy with morning sickness (NVP)
Pregnancy in Women with Multiple Sclerosis
Alcohol Use during Pregnancy
Lamisil in Pregnancy
Meridia in Pregnancy
Autoimmune Diseases in Pregnancy Project
Motherisk News: Pregnant women at high risk of complications from H1N1 influenza - Treatment options for high risk group
OTTAWA, June 15, 2009 - With the H1N1 flu outbreak now elevated to pandemic level, a new article in CMAJ (Canadian Medical Association Journal) reports that oseltamivir and zanamivir are relatively safe drugs for use in pregnant and breast-feeding women.
Pregnant women, especially those in the third trimester, are at high risk of serious complications from the H1N1 A influenza virus.
The study was conducted by researchers from the Motherisk Program at The Hospital for Sick Children (SickKids) in Toronto and the Japan Drug Information Institute in Pregnancy in Tokyo, Japan.
For treatment or prevention during the current pandemic, "oseltamivir appears to be the drug of choice because there is more data on its safety in pregnancy," says Dr. Shinya Ito, Head of the Division of of Clinical Pharmacology and Toxicology at SickKids. Zanamivir can be used, although there is less data available about its safety in pregnant women. Neither drug appears to affect the growth and development of the fetus, although ongoing data collection is important. The groups at high risk of flu-related complications from the novel H1N1 influenza are the same as those for seasonal flu - pregnant women, children under five years, the elderly and others such as those with chronic lung conditions.
Only small amounts of oseltamivir and zanamivir are excreted into human milk. If an infant is breastfed by the mother on these drugs and needs treatment, the recommended dose of oseltamivir or zanamivir should be given to the infant.